Crysvita

Burosumab, sold under the brand name Crysvita, is a human monoclonal antibody medication for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia.[5][8][9] Burosumab was approved by the FDA for its intended purpose, in patients aged one year and older, in April 2018.[10] The FDA approval fell under both the breakthrough therapy and orphan drug designations.[10][11] It was appro... [wikipedia]